Page 3 - Clinical Trials

Trials start for Equillium drug for autoimmune disease after India approval

Equillium secured exclusive rights to develop and commercialise itolizumab for the US and Canada markets, in May 2017.

AstraZeneca sets up clinical data and insights division in India

Drug firm AstraZeneca on Wednesday said it has launched a clinical data and insights division in India for data-related management of its clinical trials. The Bengaluru-based clinical data and insights (CDI) division is a critical advancement to support a growing global portfolio and build on internal data expertise, the drug firm said in a statement. The CDI division works across therapy areas and portfolios, supporting early and late-stage clinical programmes from Phase 1 to Phase 3, with an integrated end-to-end approach for clinical data, analytics, insights and risk management, it added. Currently, a 30-member team, the division is expected to grow to over 100 members by 2022, the drug firm said. "India has seen a constant uptick in investment in areas such as business services, engineering, digital, IT, R&D and product development from global Fortune-500 companies. AstraZeneca in India is no different since its inception, AstraZeneca India has supported the global ...

UK to offer new Covid-19 vaccine shots to Novavax trial volunteers

Around 15,000 people in the UK got Novavax shots as part of a clinical trial. While the UK recognizes them as vaccinated, most countries don't, meaning they can't travel

Pfizer vaccine safe for children aged 5-11, show clinical trial results

Pfizer said Monday its Covid-19 vaccine works for children ages 5 to 11 and that it will seek US authorisation for this age group soon -- a key step toward beginning vaccinations for youngsters.

Gennova's mRNA vaccine to come in powder form; will stay stable at 2-8 °C

The lyophilized vaccine will come in a powder form and it will be mixed with diluents before administration

DCGI nod to phase-I clinical trial of Reliance Life Sciences' Covid vaccine

DCGI on Friday granted permission to the Mukesh Ambani-owned Reliance Life Sciences to conduct phase-I clinical trial of its indigenous COVID-19 vaccine with certain conditions, sources said.

UK vaccine advisers decide against Covid vaccine for ages between 12-15 yrs

The UK's Chief Medical Officers will provide further advice on Covid-19 vaccination of young people aged between 12 to 15 years

Johnson & Johnson seeks nod for Covid vaccine trial on adolescents

To achieve herd immunity, studies have to be done on children, pharma major says

Cumulative Covid-19 vaccine doses administered in India exceed 528.9 mn

The cumulative Covid-19 vaccine doses administered in the country has exceeded 52.89 crore, the Union health ministry said on Thursday.

Covid-19 vaccine doses administered in India cross 510 mn: Health min

The cumulative COVID-19 vaccine doses administered in the country has crossed the landmark of 51 crore, the Union health ministry said on Monday. More than 49 lakh (49,06,273) doses have been administered on Monday, according to the 7 pm provisional report. The ministry said 26,66,611 vaccine doses were administered as first dose and 4,59,352 vaccine doses given as second dose in the age group 18-44 years on Monday. Cumulatively, 17,95,70,348 persons in the age group 18-44 years across all states and union territories have received their first dose and 1,24,91,475 have received their second dose since the start of the third phase of the vaccination drive. Five states -- Madhya Pradesh, Gujarat, Rajasthan, Maharashtra and Uttar Pradesh -- have administered more than 1 crore cumulative doses of COVID-19 vaccine in the age group 18-44 years. Also, Andhra Pradesh, Assam, Chhattisgarh, Delhi, Haryana, Jharkhand, Kerala, Telangana, Himachal Pradesh, Odisha, Punjab, Uttarakhand and West

SC notice to Centre, others on plea seeking data on Covid vaccine trials

The Supreme Court on Monday sought responses from the Centre and others on a plea seeking directions for disclosure of data regarding clinical trials of Covid-19 vaccines.

Govt recommends nod to SII for phase 2/3 trials of Covovax on children

An expert panel of India's Central Drug Authority recommended granting permission to Serum Institute of India for conducting phase 2/3 trials of Covid vaccine Covovax on children aged 2 to 17 years

Zydus Covid-19 vaccine for children soon, Centre tells Delhi High Court

This comes as the court said it would be a "disaster" if Covid-19 vaccines are administered, especially to children, without clinical trials

Hetero seeks emergency use authorisation for Merck's antiviral drug

Clinical trial shows molnupiravir helps in early recovery in non-hospitalised Covid-19 patients

Turkey starts phase-2 trials of local Covid-19 vaccine in Istanbul

The phase-2 trials of the locally developed vaccine against Covid-19 started to be administered to volunteers in Istanbul, local media reported

Bharat Biotech-Brazil row: Covaxin nod under controlled conditions

The agency said the suspension - which put the EUA application on ice - was due to missing data from the vaccine's clinical trials

Covaxin 77.8% effective against symptomatic Covid-19: Bharat Biotech

The company claimed Covaxin is the first to report promising efficacy against asymptomatic infections based on qPCR testing that will help in reducing disease transmission

Recruitment for Covaxin trial in 6-12 age group to start from June 15

The recruitment for the clinical trial of the country's first indigenously-developed COVID-19 vaccine, Covaxin, among children in the age group of 6-12 years will begin at the AIIMS here from Tuesday. This will be followed by the clinical trial of children in the age-group of 2-6 years. The enrolment of children volunteers aged 12-18 years at the All India Institute of Medical Sciences (AIIMS) has been completed and they have been given the first dose of Covaxin. "The recruitment process for the clinical trial of Covaxin among children in the age group of 6-12 years will begin from Tuesday," Dr Sanjay Rai, Professor at the Centre for Community Medicine at the AIIMS, told PTI. The Drugs Controller General of India (DCGI) had granted permission for conducting the phase 2/3 clinical trial of Bharat Biotech's Covaxin among children aged two to 18 years on May 12. The trial is to be conducted in three parts -- 175 volunteers each in the groups aged 12-18, 6-12 and 2-6 years. In the tr

Novavax Covid-19 shot shows 90% efficacy, Serum Institute starts production

On track to make 100 mn doses per month by Q3 of 2021

CSIR begins clinical trials for Niclosamide drug as Covid-19 treatment

Council of Scientific and Industrial Research (CSIR) along and Laxai Life Sciences Pvt. Ltd. on Sunday initiated Phase-II clinical trial for anti-helminitic drug Niclosamide for treatment of Covid-19.